ArticleThe Journal of clinical investigation1997
Nitric oxide inhibition of coxsackievirus replication in vitro.
Article in The Journal of clinical investigation, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 94 citations in OpenAlex.
- Identification of picornavirus proteins that inhibit de novo nucleotide synthesis during infection.PLoS pathogens · 2025Article
- The Potential Role of Nitric Oxide as a Therapeutic Agent against SARS-CoV-2 Infection.International journal of molecular sciences · 2023Review
- The Renin-Angiotensin-Aldosterone System, Nitric Oxide, and Hydrogen Sulfide at the Crossroads of Hypertension and COVID-19: Racial Disparities and Outcomes.International journal of molecular sciences · 2022Review
- Utility of NO and HNitric oxide : biology and chemistry · 2022Review
- Nitric oxide boosters as defensive agents against COVID-19 infection: an opinion.Journal of biomolecular structure & dynamics · 2022Article
- NO in Viral Infections: Role and Development of Antiviral Therapies.Molecules (Basel, Switzerland) · 2022Review
- Mechanisms and Therapeutic Strategies of Viral Myocarditis Targeting Autophagy.Frontiers in pharmacology · 2022Review
- Nitric oxide and viral infection: Recent developments in antiviral therapies and platforms.Applied materials today · 2021Review
- Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections.F1000Research · 2021Review
- Nitric oxide synthases, S-nitrosylation and cardiovascular health: from molecular mechanisms to therapeutic opportunities (review).Molecular medicine reports · 2015Review
- Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.Journal of cardiovascular translational research · 2014Review
- Gaseous nitric oxide reduces influenza infectivity in vitro.Nitric oxide : biology and chemistry · 2013Article
- Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis.European heart journal · 2011Article
- The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.Medicinal research reviews · 2011Review
- Pichinde virus induces microvascular endothelial cell permeability through the production of nitric oxide.Virology journal · 2009Article
- Role of nitric oxide in the pathogenesis of encephalomyocarditis virus-induced diabetes in mice.Journal of virology · 2009Article
- Nitric oxide in dengue and dengue haemorrhagic fever: necessity or nuisance?FEMS immunology and medical microbiology · 2009Review
- The role of nitric oxide in mycobacterial infections.Immune network · 2009Article
- Nitric oxide inhibits the replication cycle of porcine parvovirus in vitro.Archives of virology · 2009Article
- Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons.Journal of virology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Nitric oxide is a radical molecule with antibacterial, -parasitic, and -viral properties. We investigated the mechanism of NO inhibition of Coxsackievirus B3 (CVB3) replication in vitro by determining the effect of NO upon a single replicative cycle of CVB3 grown in HeLa cells. Transfection of inducible NO synthase cDNA into HeLa cells reduces the number of viral particles produced during a single cycle of growth. Similarly, a noncytotoxic concentration of the NO donor S-nitroso-amino-penicillamine reduces the number of viral particles in a dose-dependent manner. To explore the mechanisms by which NO exerts its antiviral effect, we assayed the attachment, replication, and translation steps of the CVB3 life cycle. NO does not affect the attachment of CVB3 to HeLa cells. However, NO inhibits CVB3 RNA synthesis, as shown by a [3H]uridine incorporation assay, reverse transcription-PCR, and Northern analysis. In addition, NO inhibits CVB3 protein synthesis, as shown by [35S]methionine protein labeling and Western blot analysis of infected cells. Thus, NO inhibits CVB3 replication in part by inhibiting viral RNA synthesis by an unknown mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.